Optimal management of a biochemical incomplete response to therapy in differentiated thyroid cancer: aggressive treatment or cautious observation?

[1]  F. Pitoia,et al.  Erratum to: Biochemical persistence in thyroid cancer: is there anything to worry about? , 2014, Endocrine.

[2]  A. Erika,et al.  Biochemical persistence in thyroid cancer: is there anything to worry about? , 2014, Endocrine.

[3]  R. Tuttle,et al.  Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy , 2012, Clinical endocrinology.

[4]  R. Tuttle,et al.  In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. , 2011, Thyroid : official journal of the American Thyroid Association.

[5]  G. Cevenini,et al.  Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. , 2011, European journal of endocrinology.

[6]  J. Shah,et al.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. , 2010, Thyroid : official journal of the American Thyroid Association.

[7]  R. Tuttle,et al.  Contemporary post surgical management of differentiated thyroid carcinoma. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[8]  Stephanie L. Lee,et al.  A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.